Company: RGNT
Filing Date: 2025-02-12
Form Type: DRS/A
Source: 0001213900-25-012299
Chunk: 75

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-02-12
Form: DRS/A
Chunk 75
---
 to, among other things, pay dividends or make other distributions or payments on account of our Ordinary Shares, in each case
subject to certain exceptions. If we do not pay dividends, our Ordinary Shares may be less valuable because a return on your investment
will only occur if our share price appreciates and you then sell our Ordinary Shares. In addition, our loan agreements limit our ability
to pay dividends or make other distributions or payments on account of our Ordinary Shares, in each case subject to certain exceptions.
The Companies Law imposes further restrictions on our ability to declare and pay dividends.

<div align='center'>48</div>

If we do raise additional capital, shareholders may be subject to dilution.

If we issue additional shares
of our Ordinary Shares or other equity securities convertible into share capital to fund operations, develop new products, accelerate
other strategies, make acquisitions or support other activities, the ownership interests of investors in this offering will be diluted.
Because our decision to issue debt or equity securities in any future offering will depend on market conditions and other factors beyond
our control, we cannot predict or estimate the amount, timing or nature of any future offerings. To the extent that we raise additional
capital through the sale of equity securities, your ownership interest will be diluted, and the terms may include liquidation or other
preferences that adversely affect your rights as a shareholder. The incurrence of indebtedness would result in increased fixed payment
obligations and could involve restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability
to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct
our business. Additionally, any future collaborations we enter into with third parties may provide capital in the near term but limit
our potential cash flow and revenue in the future. If we raise additional funds through strategic partnerships and alliances and licensing
arrangements with third parties, we may have to relinquish valuable rights to our technologies or product candidates, or grant licenses
on terms unfavorable to us.

Insiders will continue to have substantial influence over us after this offering, which could limit your ability to affect the outcome of key transactions, including a change of control.

After this offering, our directors,
officers, holders of more than 5% of our outstanding shares and their respective affiliates will beneficially own shares representing
approximately % of our outstanding Ordinary Shares, assuming no exercise of the Representative’s option
to purchase additional shares and additional warrants without giving effect to any shares